Cerebrolysin vs Semax
Porcine brain-derived neuropeptide preparation containing bioactive peptide fragments of neurotrophic factors, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and cognitive impairment
A brain-boosting peptide that supercharges your cognitive function by ramping up BDNF—the protein your neurons need to grow, connect, and stay sharp—all delivered through a simple nasal spray.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Cerebrolysin
20–30 mL
Semax
500–900 mcg/day
Frequency
Cerebrolysin
Once daily
Semax
Once daily
Administration
Cerebrolysin
Intravenous (IV) injection or infusion
Semax
Intranasal spray
Cycle length
Cerebrolysin
8-12 weeks
Semax
4-6 weeks
Onset speed
Cerebrolysin
Moderate (1-2 weeks)
Semax
Rapid (hours to days)
Evidence level
Cerebrolysin
Moderate human trials (Phase 1-2)
Semax
Moderate human trials (Phase 1-2)
Benefit ratings
Stroke Recovery
Alzheimer's Support
Brain Injury Healing
Cognitive Enhancement
Neuroprotection
Mental Energy
Compound specifications
Cerebrolysin
Molecular formula
Complex mixture — no single molecular formula (contains multiple peptide fragments and free amino acids derived from porcine brain proteins)
Molecular weight
Bioactive peptide components are all below 10 kDa (10,000 Da); the preparation contains a spectrum of peptide sizes
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
~85-100% (intramuscular injection)
CAS number
Not assigned (biological mixture)
Semax
Molecular formula
C37H51N9O10S
Molecular weight
813.9 g/mol
Half-life
Several minutes to hours (intranasal effects persist longer)
Bioavailability
High via intranasal route (directly reaches brain)
CAS number
80714-61-0
Dosing compared
Cerebrolysin
Intravenous
10 mL
Once daily · 10-20 day course, repeated every 3-6 months
A gentle starting dose given as a slow IV infusion (often diluted in saline). Used in dementia and recovery programs. [6][7]
20-30 mL
Once daily · 10-21 day course, repeated in cycles
The common clinical dose. Trials in vascular dementia used 20 mL daily, and stroke trials used 30 mL daily (diluted to about 100 mL saline) infused over ~30 minutes. [6][7]
30-50 mL
Once daily · 10-21 days for stroke or severe brain injury
The higher end used for acute stroke and severe traumatic brain injury, given as a diluted IV infusion under medical supervision. [7]
Intramuscular
5-10 mL
Once daily · Up to 10-20 days per course
For smaller doses, Cerebrolysin can be given as an intramuscular injection (no more than ~5 mL per injection site). Often used for milder cases or maintenance between IV cycles. [7]
Semax
Intranasal
250-500 mcg/day
Once or twice daily · 1-2 weeks
Cognitive/nootropic practice with the 0.1% solution; downstream BDNF/NGF effects persist 12-24 h so dosing is once to twice daily [1][2].
500-900 mcg/day
Divided 2-3 times daily · 3-4 weeks
Mid-range nootropic practice dose; upregulates hippocampal BDNF/TrkB in animal models [1][2][3].
Best suited for
Cerebrolysin
Post-stroke neurorecovery and rehabilitation support
Cerebrolysin is particularly well-suited for individuals focused on post-stroke neurorecovery and rehabilitation support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2][13].
Cognitive support in Alzheimer's disease and vascular dementia
Cerebrolysin is particularly well-suited for individuals focused on cognitive support in alzheimer's disease and vascular dementia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
Traumatic brain injury recovery and neuroprotection
Cerebrolysin is particularly well-suited for individuals focused on traumatic brain injury recovery and neuroprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [14].
Age-related cognitive decline and mild cognitive impairment
Cerebrolysin is particularly well-suited for individuals focused on age-related cognitive decline and mild cognitive impairment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Semax
Students and Knowledge Workers
If your day revolves around learning, studying, or processing complex information, Semax can be a game-changer. It enhances memory consolidation and recall while improving your ability to focus for extended periods—perfect for exam prep or demanding projects [6][12].
Those Seeking Mental Clarity
Brain fog? Semax works by boosting BDNF—the protein that helps neurons communicate effectively. [1][2] Users often report feeling like the 'mental static' clears away, leaving sharper, more efficient thinking in its place.
Neuroprotection Seekers
Beyond immediate cognitive benefits, Semax offers protective effects for your brain cells. [9] It acts as an antioxidant (especially against copper toxicity) [4][8] and supports neuronal health—valuable for anyone concerned about long-term brain wellness.
Recovery Support (Under Medical Supervision)
In Russia, Semax is approved for helping stroke patients and those with traumatic brain injuries recover cognitive function. [6] While not FDA-approved for this use elsewhere, the research shows meaningful neuroprotective and neurorestorative properties [7][9].
Side effects
Cerebrolysin
Common
- Injection site reactions
- Headache
- Dizziness and vertigo
- Nausea and gastrointestinal discomfort
- Agitation or restlessness
- Fever
Uncommon
- Allergic reaction
Serious
- Severe hypersensitivity reaction
Semax
Common
- Nasal irritation
- Mild headache
- Increased alertness
Uncommon
- Temporary blood pressure increase
- Dizziness
Serious
- Allergic reaction
Safety & evidence
Cerebrolysin
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cerebrolysin is an FDA-unregulated neuroprotective agent consisting of porcine brain-derived peptides and amino acids that has been used primarily in Eastern Europe and Asia. [8][12] Safety data is limited to observational clinical use and small open-label trials rather than rigorous randomized controlled trials with formal safety monitoring. As a complex mixture of undefined peptide fragments from animal sources, batch consistency and sterility cannot be guaranteed without pharmaceutical manufacturing standards. Potential allergic reactions to porcine proteins and transmissible spongiform encephalopathy (TSE) risks from animal-derived components have not been adequately ruled out.
Contraindications
- Known hypersensitivity to Cerebrolysin or porcine-derived products
- Severe renal impairment or renal failure
- Status epilepticus or uncontrolled epilepsy
- Pregnancy and breastfeeding — insufficient safety data
Semax
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Semax has been used clinically in Russia for over 25 years with an excellent safety profile. [7][12] It's approved there for treating stroke, cognitive impairment, and optic nerve diseases. [6] Studies consistently show minimal side effects, mostly limited to mild nasal irritation when using the spray form. [6][9] Unlike stimulants, Semax doesn't appear to cause tolerance, dependence, or withdrawal symptoms even with extended use.
Contraindications
- Pregnancy or planning to become pregnant
- Currently breastfeeding
- History of seizures or epilepsy
- Known allergy to ACTH-related peptides
- Uncontrolled hypertension
Which is right for you?
Choose Cerebrolysin if...
- Post-stroke neurorecovery and rehabilitation support
- Cognitive support in Alzheimer's disease and vascular dementia
- Traumatic brain injury recovery and neuroprotection
- Age-related cognitive decline and mild cognitive impairment
Choose Semax if...
- Cognitive enhancement
- Memory improvement
- Focus and concentration
- Neuroprotection